[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pulsed-field-ablation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pulsed-field-ablation":355},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,49,83,104,129,156,186,213,239,265,286,306,332],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100644942","atrial-remodeling-after-pfa-substrate-modification-for-persistent-af-peaf-100644942",false,"NCT07675395","Atrial Remodeling After PFA Substrate Modification for Persistent AF (PeAF)","Pulsed-Field Ablation for Persistent Atrial Fibrillation: Impact of Atrial Remodeling After Substrate Modification","Inclusion Criteria:\n\n* Diagnosis of persistent atrial fibrillation\n* Left atrial anteroposterior (AP) diameter greater than 4 cm and less than 6 cm\n* Anti-arrhythmic medications (except amiodarone) discontinued for at least 5 half-lives before the procedure\n* No use of beta-blockers or diuretics before or after the ablation procedure\n* Willing and able to provide written informed consent\n\nExclusion Criteria:\n\n* Paroxysmal atrial fibrillation\n* Previous left atrial surgery or catheter ablation procedure, including left atrial appendage closure\n* Atrial fibrillation due to reversible causes, such as thyroid disorders, acute alcohol intoxication, or other major surgeries within the 90 days preceding the procedure\n* Myocardial infarction, acute coronary syndrome, percutaneous coronary intervention, or coronary artery bypass grafting within 90 days of the procedure\n* Known presence of cardiac thrombus\n* Stroke or transient ischemic attack within the last 90 days\n* Any other anatomical or comorbid condition that, in the investigator's opinion, could limit the patient's ability to participate in the clinical trial, comply with follow-up requirements, or impact the scientific validity of the clinical trial results","ALL","18 Years",{"count":19,"type":20},30,"ESTIMATED","INTERVENTIONAL",[23],"NA","Atrial fibrillation (AF) is associated with both electrical and structural remodeling of the left atrium. While successful catheter ablation has been shown to reverse some aspects of atrial remodeling, the impact of pulsed-field ablation (PFA) - a non-thermal ablation technology that selectively targets cardiomyocytes while sparing surrounding structures - on atrial remodeling in patients with persistent AF undergoing extensive substrate modification remains unclear.\n\nThis is a prospective, single-center, single-arm observational study conducted at Taipei Veterans General Hospital. The study will enroll 30 patients with persistent atrial fibrillation who undergo pulmonary vein isolation (PVI) and extensive substrate modification using the FARAWAVE \u002F FARADRIVE Catheter and FARASTAR System.\n\nThe primary objective is to evaluate left atrial structural remodeling following PFA, including changes in LA size, atrial strain, extent of atrial fibrosis, and atrial hemodynamic function. The secondary objective is to assess AF-free survival between 3 and 12 months after the procedure, and its relationship to atrial remodeling. All participants will be followed for 12 months, with an interim analysis conducted once all subjects complete their 6-month follow-up.",[26,27,28,29],"Persistent Atrial Fibrillation","Atrial Fibrillation (AF)","Atrial Remodeling","Pulsed Field Ablation",[29,26,31,28,32,33,34,35],"Atrial Fibrillation","Substrate Modification","Atrial Fibrosis","Cardiac MRI","Posterior Wall Isolation","NOT_YET_RECRUITING","2026-06-30",{"date":39,"type":40},"2026-07-02","ACTUAL",{"date":42,"type":20},"2026-07-01",{"date":44,"type":20},"2028-12-31",{"name":46,"class":47},"Taipei Veterans General Hospital, Taiwan","OTHER_GOV",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":21,"phases":59,"briefSummary":60,"conditions":61,"keywords":66,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":82},"100619784","option-emea-clinical-trial-100619784","NCT07349121","OPTION-EMEA Clinical Trial","Concomitant Left Atrial Appendage Closure and Pulsed Field Ablation - Europe, Middle East and Africa [OPTION-EMEA]","OPTION-EMEA","Inclusion Criteria:\n\n1. Clinically indicated for treatment with both the FARAPULSE™ PFA system and with WATCHMAN FLX™ Pro or WATCHMAN FLX™ for LAAC, per physician medical judgement and as per hospitals' standard of care.\n2. Subjects who are willing and able to provide informed consent.\n3. Subjects who are willing and able to participate in all testing associated with this clinical study at an approved investigational center.\n4. Subjects whose age is 18 years or above, or who are of legal age to give informed consent specific to state and national law.\n\nExclusion Criteria:\n\n1. Subjects who underwent prior AF ablation procedure.\n2. Subjects with atrial fibrillation that is secondary to electrolyte imbalance, thyroid disease, alcohol, or other reversible \u002F non-cardiac causes.\n3. Already surgically closed or otherwise excluded LAA.\n4. The LAA anatomy does not accommodate a Closure Device.\n5. Known or suspected atrial myxoma.\n6. Presence of intracardiac thrombus\\*.\n7. Subjects with a current interatrial baffle or patch, history of atrial septal repair or has an atrial septal defect (ASD) \u002F patent foramen ovale (PFO) device.\n8. Subjects with a presence of a mechanical valve prosthesis in any position.\n9. Subjects with a myocardial infarction within 90 days prior to enrollment.\n10. Subjects had a prior stroke (of any cause, whether ischemic or hemorrhagic) or transient ischemic attack (TIA) within 90 days prior to enrollment.\n11. Any planned electrical cardioversion within 30 days following LAAC device implant.\n12. Subjects with a known inability to obtain vascular access.\n13. Subjects with any contraindication to percutaneous catheterization procedure (e.g., patient size does not accommodate required catheters, ventriculotomy or atriotomy) or congenital abnormalities (severe rotational anomalies of the heart or great vessels) are present.\n14. Subjects with any active conditions (e.g. infection, bleeding disorder, unstable angina).\n15. Subjects with any contraindications to short term use of anticoagulation therapy for conditions different from atrial fibrillation.\n16. Subjects who are pregnant or planning to be pregnant.\n17. Subjects with a life expectancy of ≤ 1 year per investigator's opinion.\n18. Subjects who are currently enrolled in another investigational study or registry that would directly interfere with the current study, except when the subject is participating in a mandatory governmental registry, or a purely observational registry with no associated treatments. Each instance must be reviewed by the sponsor to determine eligibility.",{"count":58,"type":20},500,[23],"The OPTION-EMEA post-market study is intended to gather real world clinical data for patients undergoing AF ablation with the FARAPULSE™ Pulsed Field Ablation (PFA) System and subsequent left atrial appendage closure (LAAC) with a WATCHMAN FLX™ Pro or WATCHMAN FLX device during one interventional case.\n\nThe study will include patients that are clinically indicated for atrial fibrillation (AF) ablation using the FARAPULSE PFA System and for left atrial appendage closure (LAAC) treatment using a WATCHMAN FLX Pro or WATCHMAN FLX device as part of the patient's standard of care determined by their doctor's medical judgement.",[27,62,63,29,64,65],"Stroke Prevention in Patients With Atrial Fibrillation","Left Atrial Appendage Closure","Atrial Fibrillation Ablation Procedure","Concomitant Procedures",[67,68,69,70,71],"WATCHMAN","FARAPULSE","Concomitant","PFA","LAAC","RECRUITING","2026-06-26",{"date":37,"type":40},{"date":76,"type":40},"2026-06-18",{"date":78,"type":20},"2029-12",{"name":80,"class":81},"Boston Scientific Corporation","INDUSTRY",3,{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":87,"acronym":4,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":89,"targetDuration":4,"studyType":90,"phases":4,"briefSummary":91,"conditions":92,"keywords":4,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":48},"100610378","nanosecond-pulsed-field-ablation-in-the-management-of-benign-thyroid-nodules-100610378","NCT07226804","Nanosecond Pulsed Field Ablation in the Management of Benign Thyroid Nodules","Eligibility Criteria\n\n* Scheduled to undergo ultrasound guided nsPFA as standard of care\n* Age 18 to 80 years.\n* Capable of providing independent consent.\n* Presence of biopsy-confirmed benign thyroid nodule , defined as one of the following:\n\n  * Benign FNA X 2 or\n  * Benign US guided FNA X 1 + benign thyroid nodule ultrasound appearance (TI-RADS 2) or\n  * Benign FNA X 1 and radiographic\u002Flaboratory evidence of functional nature\n* Nodule measuring \\>2cm in greatest dimension\n* Presence of compressive symptoms reasonably attributable to thyroid nodule (i.e. pressure sensation, dysphagia, dysphonia, respiratory distress)\n* No abnormal cervical lymph nodes during screening visit .\n\nExclusion Criteria\n\n* Age \\\u003C18\n* Patients considered unsuitable for nsPFA by the treating physician",{"count":19,"type":20},"OBSERVATIONAL","To observe the outcomes of nsPFA therapy to treat benign thyroid nodules.",[93,29],"Thyroid Nodules","2026-05-29",{"date":96,"type":40},"2026-06-01",{"date":98,"type":40},"2025-11-14",{"date":100,"type":20},"2030-08-31",{"name":102,"class":103},"M.D. Anderson Cancer Center","OTHER",{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":110,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":112,"targetDuration":4,"studyType":21,"phases":114,"briefSummary":115,"conditions":116,"keywords":4,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":48},"100639560","pulsed-field-ablation-outcomes-with-efficacy-and-randomization-in-atrial-fibrillation-power-af-100639560","NCT07601763","Pulsed Field Ablation Outcomes With Efficacy and Randomization in Atrial Fibrillation (POWER-AF)","Pulsed Field Ablation for Atrial Fibrillation Including Posterior Wall and Linear Ablation: A Randomized Controlled Trial of Safety and Efficacy (POWER-AF)","POWER-AF","Inclusion Criteria:\n\n1. Atrial fibrillation patients who will accept catheter ablation.\n2. Age ≥ 18.\n3. Be capable of understanding and signing the informed consent form.\n\nExclusion Criteria:\n\n1. Have contraindications for catheter ablation (such as atrial thrombosis, decompensated heart failure, etc.)\n2. Have accepted catheter ablation before.\n3. Myocardial infarction, or any cardiac interventional\u002Fsurgery has been performed within 3 months.\n4. Had a stroke or transient ischemic attack within 6 months.\n5. Allergy to iodine contrast agents.\n6. Participate in clinical trials related to other drugs or devices.\n7. Pregnant women, lactating women, or women with plans to become pregnant shortly.\n8. Active stage of infection.\n9. Secondary atrial fibrillation, such as combined with rheumatic heart disease, hypertrophic cardiomyopathy, etc.\n10. Patients who do not agree to be enrolled or are unable to cooperate to complete the study",{"count":113,"type":20},1574,[23],"Atrial fibrillation (AF) is one of the most common arrhythmias in clinical practice. As of 2019, there were approximately 59.7 million patients with AF worldwide, including atrial flutter (AF). Atrial fibrillation can significantly increase the risks of stroke, thromboembolism and heart failure in patients, seriously affecting their quality of life.\n\nCatheter ablation is the main means for rhythm control in patients with atrial fibrillation. A large number of clinical studies have confirmed the effectiveness and safety of catheter ablation for atrial fibrillation. It is significantly superior to drug treatment in maintaining sinus rhythm and can significantly improve symptoms and quality of life.\n\nPulsed electric field ablation (PFA) is a novel ablation method that utilizes pulsed electric fields as energy. It uses multiple short-duration and high-voltage electrical pulses to release ablation energy, selectively causing myocardial cells to rupture and die. However, it has no obvious damaging effect on blood vessels, nerves, and tissues around the heart, such as the lungs, esophagus, and phrenic nerve.\n\nThis trial was designed based on the advantage of the characteristic that PFA does not damage the esophagus, confining the damage to the posterior half of the left atrium and the circumferential isthmus of the mitral valve. While improving the ablation success rate, it is possible to protect the function of the left atrium. This study aims to verify the superiority of the new rhythm control strategy in a large-scale population by launching a prospective randomized controlled trial.",[27,117,118,29,119],"Atrial Fibrillation Ablation","Atrial Fibrillation Recurrent","Radiofrequency Catheter Ablation","2026-05-24",{"date":122,"type":40},"2026-05-28",{"date":124,"type":40},"2025-04-16",{"date":126,"type":20},"2028-11-30",{"name":128,"class":47},"China National Center for Cardiovascular Diseases",{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":133,"acronym":134,"eligibilityCriteria":135,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":136,"targetDuration":4,"studyType":21,"phases":138,"briefSummary":140,"conditions":141,"keywords":143,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":152,"leadSponsor":154,"locationsCount":48},"100620176","phase-4-workflow-optimization-during-pulse-field-ablation-for-atrial-fibrillation-100620176","NCT07354217","Workflow Optimization During Pulse Field Ablation for Atrial Fibrillation","PFA_workflow","Inclusion Criteria:\n\n1. Patients with paroxysmal or persistent AF and are scheduled to undergo PVI.\n2. Patients who can understand the study aims and protocol and are willing to follow the protocol for one year.\n\nExclusion Criteria:\n\n1. Informed consent could not be obtained\n2. Known allergy to study drug lidocaine.\n3. Presence of thrombus in the LA or LA appendage\n4. Underlying significant pulmonary disease, such as asthma or COPD needing long term maintenance therapy or documented interstitial lung disease",{"count":137,"type":20},60,[139],"PHASE4","To evaluate the efficacy and safety of intravenous lidocaine in reducing diaphragmatic contraction and suppressing the cough reflex during pulsed field ablation procedures.",[29,142],"Lidocaine",[144,145,146,147],"Pulmonary Vein Isolation","LIDOCAINE","Pulse Field Ablation","cough suppression","2026-04-16",{"date":150,"type":40},"2026-04-20",{"date":96,"type":20},{"date":153,"type":20},"2030-12-31",{"name":155,"class":103},"National Taiwan University Hospital",{"id":157,"slug":158,"hasResults":11,"nctId":159,"briefTitle":160,"officialTitle":161,"acronym":4,"eligibilityCriteria":162,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":163,"targetDuration":4,"studyType":21,"phases":165,"briefSummary":166,"conditions":167,"keywords":168,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":180,"completionDateStruct":182,"leadSponsor":184,"locationsCount":48},"100602996","comparative-intra-procedural-evaluation-of-farapulse-and-farawave-nav-catheters-100602996","NCT07130773","Comparative Intra-procedural Evaluation of Farapulse and FARAWAVE Nav Catheters","Procedural Comparative Evaluation of Pulmonary Vein Isolation Using the FARAWAVE Nav PFA Catheter Without Pre-Ablation Computer Tomography (CT) vs. Conventional Farapulse With Pre-Ablation CT: A Single Centre Open-label, Randomized Controlled Trial","Inclusion Criteria:\n\n* Atrial fibrillation (AF) documented on a 12-lead ECG, Holter monitor, or implantable cardiac device.\n* Candidate for ablation according to current atrial fibrillation guidelines.\n* Age ≥18 years at the time of informed consent.\n* Signed informed consent obtained\n\nExclusion Criteria:\n\n* Previous left atrial ablation or left atrial surgery.\n* Presence of intracardiac thrombus.\n* Persistent atrial fibrillation lasting \\>3 years.\n* Severe mitral regurgitation or moderate-to-severe mitral stenosis.\n* Pregnancy (all women under 50 years undergo an HCG blood test prior to inclusion to exclude pregnancy).",{"count":164,"type":20},58,[23],"The FARAPULSE PFA catheter (Boston Scientific), a first-generation Pulsed Field Ablation (PFA) tool, has demonstrated good performance in isolating pulmonary veins (PV). Several centers, including ours, utilize pre-procedural computer tomography (CT) to evaluate individual pulmonary vein anatomy and optimize ablation planning. However, these imaging modalities are costly. Additionally, CT imaging exposes patients to radiation, and introduce significant logistical challenges to the procedural workflow.\n\nThe FARAWAVE Nav PFA catheter, a second-generation device, integrates magnetic navigation capabilities with detailed mapping and PFA therapy into a single tool. This system leverages the FARAVIEW Software Module, offering tailored mapping solutions visualized on the FARAPULSE PFA system, including the creation of voltage and activation maps.\n\nThese features address the limitations of the first-generation FARAPULSE catheter and have the potential to improve procedural accuracy and the durability of pulmonary vein isolation. Moreover, they may obviate the need for pre-procedural CT, thereby reducing costs and minimizing patient radiation exposure.\n\nOur study evaluates whether the FARAWAVE Nav catheter, used without pre-ablation CT, allows for a reduction in fluoroscopy time and overall patient radiation exposure compared to the conventional workflow with the FARAPULSE catheter. Furthermore, we will assess procedural time, costs, number of PFA applications, and AF recurrence-free survival",[27,117,29],[169,170,171,172,173,174,175,176],"pulsed filed ablation","atrial fibrillation","ablation","pulmonary vein isolation","electroanatomical map","ionizing radiation","farapulse","farawave nav","2026-03-17",{"date":179,"type":40},"2026-03-19",{"date":181,"type":40},"2025-11-10",{"date":183,"type":20},"2026-12",{"name":185,"class":103},"Cardiocentro Ticino",{"id":187,"slug":188,"hasResults":11,"nctId":189,"briefTitle":190,"officialTitle":191,"acronym":192,"eligibilityCriteria":193,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":194,"enrollmentInfo":195,"targetDuration":4,"studyType":90,"phases":4,"briefSummary":197,"conditions":198,"keywords":200,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":203,"lastUpdatePostDateStruct":204,"startDateStruct":206,"completionDateStruct":208,"leadSponsor":210,"locationsCount":4},"100617023","pulsed-field-ablation-for-non-valvular-atrial-fibrillation-after-left-atrial-appendage-occlusion-100617023","NCT07313228","Pulsed Field Ablation for Non-valvular Atrial Fibrillation After Left Atrial Appendage Occlusion","Pulsed Field Ablation of Non-valvular Atrial Fibrillation After Left Atrial Appendage Occlusion: A Prospective, Single-center, Single-arm Clinical Trial","PFA after LAAO","Inclusion Criteria:\n\n1. Aged 18-75 years;\n2. Documented symptomatic atrial fibrillation;\n3. Ineffective or intolerant to at least one class I or III antiarrhythmic drug;\n4. Able to fully understand the treatment protocol, voluntarily sign the informed consent form, and willing to undergo the required examinations, procedures, and follow-up.\n\nExclusion Criteria:\n\n1. Patients who have previously undergone left atrial surgery;\n2. Left atrial thrombus;\n3. Patients with pulmonary agenesis;\n4. Female patients of reproductive age who cannot use effective contraception within 12 months after enrollment;\n5. Left atrial anteroposterior diameter ≥ 55 mm;\n6. Left ventricular ejection fraction (LVEF) ≤ 40%;\n7. Patients who have previously undergone interatrial septal repair or removal of atrial myxoma;\n8. Patients with active implanted devices (e.g., pacemaker, ICD);\n9. Patients with NYHA heart failure class III-IV;\n10. Patients with a clear history of cerebrovascular disease (including cerebral hemorrhage, stroke, or TIA) within the past 6 months;\n11. Patients who have experienced cardiovascular events (e.g., acute myocardial infarction, coronary intervention or bypass surgery, valve replacement or repair, atrial or ventricular surgery) within the past 3 months;\n12. Patients with acute or severe systemic infections;\n13. Patients with severe liver or kidney disease, malignancy, or end-stage disease that may affect the treatment, assessment, or compliance of the trial (as judged by the investigator);\n14. Patients with significant bleeding tendency, hypercoagulable state, or severe hematologic disorders;\n15. Patients who have participated or are currently participating in another clinical trial within the past 12 months prior to enrollment;\n16. Patients who the investigator deems unsuitable for participation in this trial.","75 Years",{"count":196,"type":20},70,"This is a single-center, prospective, single-arm clinical trial designed to evaluate the safety and efficacy of pulsed field ablation (PFA) after left atrial appendage occlusion (LAAO) in patients with non-valvular atrial fibrillation (AF). The trial will include patients who have undergone successful LAAO and have symptomatic AF that is refractory to or intolerant of class I or III antiarrhythmic drugs. The primary objective is to assess the effectiveness of PFA in preventing AF recurrence and its safety, including the occurrence of serious adverse events. Patients will be followed up for 12 months post-procedure to evaluate outcomes such as recurrence of AF, complications, and device-related issues.",[31,199,29],"Left Atrial Appendage Occlusion",[31,201,202],"left atrial appendage occlusion","pulsed field ablation","2025-12-17",{"date":205,"type":40},"2025-12-31",{"date":207,"type":20},"2025-12",{"date":209,"type":20},"2027-06",{"name":211,"class":212},"First Affiliated Hospital of Ningbo University","NETWORK",{"id":214,"slug":215,"hasResults":11,"nctId":216,"briefTitle":217,"officialTitle":217,"acronym":218,"eligibilityCriteria":219,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":220,"targetDuration":222,"studyType":90,"phases":4,"briefSummary":223,"conditions":224,"keywords":226,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":231,"lastUpdatePostDateStruct":232,"startDateStruct":234,"completionDateStruct":236,"leadSponsor":237,"locationsCount":48},"100607196","spanish-registry-of-redo-procedures-following-pulmonary-vein-ablation-by-pulsed-field-ablation-technology-reset-pfa-100607196","NCT07185412","Spanish Registry of Redo Procedures Following Pulmonary Vein Ablation by Pulsed Field Ablation Technology: RESET-PFA","RESET-PFA","Inclusion Criteria:\n\n* Patients with an indication to a pulsed-field ablation procedure of Atrial Fibrillation according to current international and local guidelines (and future revisions), existing IFU or per physician discretion\n* Patients who are willing and capable of providing informed consent, participating in all testing at an approved clinical investigational center or such consent will be provided by a legal representative, if required by local law or regulation.\n\nExclusion Criteria:\n\n* Patients who are currently enrolled in another investigational study or registry that would directly interfere with the current study, except when the subject is participating in a mandatory governmental registry, or a purely observational registry with no associated treatments\n* Patients who are unwilling or unable to sign an authorization to use and disclose health information or an Informed Consent.\n* Patients unavailable or not willing to complete follow up visits and examination for the duration of the study at the center.\n* Life expectancy ≤ 12 months per physician judgment.",{"count":221,"type":20},1100,"1 Year","RESET-PFA is a prospective, multicenter, non-randomized post-market study. All patients will be treated according to the standard care followed by each center. The protocol requires enrollment of consecutive patients from each center, according to eligibility criteria. During the 12 months follow-up period, clinical atrial fibrillation recurrence, occurrence of all kinds of atrial arrhythmias and of all Adverse Events in the study population will be collected.\n\nThe purpose of this study is to prospectively evaluate during time a large population of patients with an indication for ablation of AF, collecting data on procedural success in the acute and medium- to long-term follow-up. The primary objective of the study is the determination of up to 10 clinical and procedural parameters predicting a repeat ablation procedure after the blanking period in patients that had undergone an AF ablation with pulsed field ablation through a standard of care pathway.",[225,31,29],"Cardiac Arrhythmia",[29,227,228,229,230],"Atrial fibrillation","Pulmonary vein isolation","Redo procedure","Mapping system","2025-09-15",{"date":233,"type":40},"2025-09-22",{"date":235,"type":20},"2025-10-01",{"date":153,"type":20},{"name":238,"class":103},"Instituto de Investigación Sanitaria Aragón",{"id":240,"slug":241,"hasResults":11,"nctId":242,"briefTitle":243,"officialTitle":243,"acronym":244,"eligibilityCriteria":245,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":246,"enrollmentInfo":247,"targetDuration":4,"studyType":21,"phases":249,"briefSummary":250,"conditions":251,"keywords":253,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":256,"lastUpdatePostDateStruct":257,"startDateStruct":259,"completionDateStruct":261,"leadSponsor":263,"locationsCount":48},"100603840","electroporation-vs-radiofrequency-ablation-guided-by-3d-imaging-in-repeat-procedures-for-atrial-fibrillation-100603840","NCT07141745","Electroporation vs. Radiofrequency Ablation Guided by 3D Imaging in Repeat Procedures for Atrial Fibrillation","ERA-rePVI","Inclusion Criteria:\n\nDocumented recurrence of AF or atypical atrial flutter after prior PVI Eligibility for re-PVI\n\nExclusion Criteria:\n\nLeft ventricular ejection fraction \\\u003C 30% Left atrial volume index (LAVI) \\> 72 mL\u002Fm² Untreated hyperthyroidism Hypertrophic cardiomyopathy Severe valvular heart disease","85 Years",{"count":248,"type":20},250,[23],"This is a prospective, randomized clinical trial evaluating the efficacy and safety of two techniques for repeat catheter ablation in patients with recurrent atrial fibrillation (AF): thermal energy ablation (radiofrequency) and non-thermal electroporation (pulsed field ablation), both guided by 3D imaging systems.\n\nPatients undergoing repeat AF ablation will be randomly assigned to receive either thermal or electroporation ablation, performed according to standard hospital protocols. No additional invasive procedures are required. Following the ablation, participants will attend follow-up visits at 3, 6, and 12 months, including medical history review, physical examination, 12-lead ECG, and 24-hour Holter monitoring. Unscheduled ECG assessments will also be available if arrhythmia symptoms occur.\n\nAll study-related procedures are non-invasive and align with routine post-ablation care. Risks are limited to those typically associated with standard AF ablation procedures.\n\nThe main benefit of participation is close, structured follow-up by experienced electrophysiologists, allowing for early detection of arrhythmia recurrence and timely medical intervention when necessary.\n\nParticipant confidentiality and data protection will be ensured in accordance with GDPR regulations.",[27,252,119,29],"Ablation Techniques",[254,29,119,255],"Atrial fibrillation re-ablation","Atrial firbillation reccurence","2025-08-26",{"date":258,"type":40},"2025-08-27",{"date":260,"type":20},"2025-08-30",{"date":262,"type":20},"2028-10-01",{"name":264,"class":103},"Wroclaw Medical University",{"id":266,"slug":267,"hasResults":11,"nctId":268,"briefTitle":269,"officialTitle":269,"acronym":270,"eligibilityCriteria":271,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":272,"targetDuration":273,"studyType":90,"phases":4,"briefSummary":274,"conditions":275,"keywords":4,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":278,"lastUpdatePostDateStruct":279,"startDateStruct":281,"completionDateStruct":283,"leadSponsor":285,"locationsCount":48},"100601334","registry-of-atrial-arrhythmia-ablation-procedures-using-pulsed-field-ablation-in-poland-100601334","NCT07109141","Registry of Atrial Arrhythmia Ablation Procedures Using Pulsed Field Ablation in Poland","PFA Registry","Inclusion Criteria:\n\n* Informed consent obtained from the participant\n* Subject is undergoing ablation of an atrial arrhythmia using the PFA\n\nExclusion Criteria:\n\n\\-",{"count":58,"type":20},"12 Months","The aim of the described project is to establish a multicenter, nationwide registry of atrial arrhythmia ablation procedures using the Pulsed Field Ablation (PFA) method. These procedures have only recently begun to be performed in several centers across Poland. With proper coordination of the registry, this will enable the consolidation of clinical data and the expansion of knowledge regarding the efficacy and safety of these procedures.",[27,276,277,252,29],"Atrial Flutter","Atrial Tachycardia","2025-07-31",{"date":280,"type":40},"2025-08-07",{"date":282,"type":40},"2024-08-01",{"date":284,"type":20},"2030-07-01",{"name":264,"class":103},{"id":287,"slug":288,"hasResults":11,"nctId":289,"briefTitle":290,"officialTitle":291,"acronym":4,"eligibilityCriteria":292,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":293,"targetDuration":4,"studyType":90,"phases":4,"briefSummary":295,"conditions":296,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":297,"lastUpdatePostDateStruct":298,"startDateStruct":300,"completionDateStruct":302,"leadSponsor":304,"locationsCount":4},"100594729","3d-guided-pulsed-field-ablation-for-paroxysmal-af-100594729","NCT07023237","3D-Guided Pulsed Field Ablation for Paroxysmal AF","Three-Dimensional Guidance for Pulmonary Vein Isolation in Patients With Paroxysmal Atrial Fibrillation: A Study on Efficacy and Safety","\\*\\*Inclusion Criteria:\\*\\*\n\n1. Aged 18 years or older, regardless of gender.\n2. Patients with paroxysmal atrial fibrillation scheduled for catheter ablation.\n3. Willing and able to comply with all follow-up requirements and agree to participate in this study.\n\n\\*\\*Exclusion Criteria:\\*\\*\n\n1. Previous left atrial catheter ablation.\n2. Left ventricular ejection fraction (LVEF) \\\u003C 35%.\n3. Left atrial diameter (assessed by echocardiography) \\> 55 mm.\n4. Presence of definite thrombus in the left atrium or any other cardiac chamber detected before surgery.\n5. Patients with New York Heart Association (NYHA) functional class III-IV heart failure.\n6. Patients with second-degree (Type II) or third-degree atrioventricular block.\n7. Significant congenital heart defects (e.g., atrial septal defect or severe pulmonary vein stenosis, but not including patent foramen ovale).\n8. Patients with prosthetic heart valves.\n9. Patients with implanted cardiac pacemakers or implantable cardioverter-defibrillators (ICDs).\n10. Patients diagnosed with hypertrophic cardiomyopathy, chronic obstructive pulmonary disease, or myxoma.\n11. Patients with known symptomatic carotid artery stenosis before surgery.\n12. Patients with untreated or uncontrolled hyperthyroidism or hypothyroidism.\n13. Patients with systemic active infections.\n14. Patients with significant bleeding tendencies or those undergoing hemodialysis for renal failure.\n15. Patients who have experienced a myocardial infarction or undergone any cardiac intervention\u002Fopen-heart surgery within the past 3 months.\n16. Patients who have had a stroke or transient ischemic attack within the past 6 months.\n17. Patients with significant contraindications to interventional procedures, as determined by the investigator, who are unable to undergo ablation surgery.\n18. Pregnant or breastfeeding women, or those planning to conceive during the study period.\n19. Patients who have participated in other drug or medical device clinical trials within the past 3 months.\n20. Patients whom the investigator deems unsuitable for participation in this clinical trial.",{"count":294,"type":20},430,"Atrial fibrillation (AF) is a common arrhythmia, especially in the elderly, and can lead to severe complications like stroke and heart failure. In China, AF affects approximately 20 million adults, and its prevalence is expected to rise due to aging \\[1, 2\\]. Catheter ablation has become a first-line treatment for AF, with pulsed field ablation (PFA) gaining attention due to its tissue selectivity and non-thermal ablation properties \\[3-8\\]. PFA uses high-voltage electric fields to create cell membrane perforations, leading to permanent tissue damage and effective arrhythmia treatment \\[6-8\\].\n\nRecent studies have shown that PFA is highly effective and safe. For example, the EU-PORIA study reported a 99.96% pulmonary vein isolation (PVI) rate with a 3.6% complication rate \\[9, 10\\], while the ADVENT study demonstrated similar efficacy to thermal ablation but with shorter procedure times \\[12\\]. However, current PFA systems often lack integration with 3D mapping systems, limiting their application in complex cases and increasing reliance on fluoroscopy \\[13, 14\\].\n\nIn China, domestic PFA technology is rapidly evolving, with a focus on expanding indications and integrating 3D techniques \\[19, 20\\]. The investigators have conducted preliminary studies on the feasibility and safety of domestic PFA in persistent AF treatment \\[21\\]. To further advance PFA, larger-scale clinical studies are needed to optimize procedural workflows and reduce complications.\n\nThis study aims to enroll 430 participants through a single-center, single-arm approach. By following up for one year, the investigators will optimize the PFA procedure under 3D guidance to enhance success rates and safety. This will support the clinical promotion of PFA technology and provide valuable data for the development of domestic PFA devices.",[27,29],"2025-06-12",{"date":299,"type":40},"2025-06-15",{"date":301,"type":20},"2025-06-30",{"date":303,"type":20},"2026-08-15",{"name":305,"class":103},"Beijing Anzhen Hospital",{"id":307,"slug":308,"hasResults":11,"nctId":309,"briefTitle":310,"officialTitle":310,"acronym":4,"eligibilityCriteria":311,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":312,"targetDuration":4,"studyType":21,"phases":313,"briefSummary":314,"conditions":315,"keywords":318,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":324,"lastUpdatePostDateStruct":325,"startDateStruct":327,"completionDateStruct":329,"leadSponsor":330,"locationsCount":4},"100590589","empiric-pulsed-field-pulmonary-vein-isolation-during-atrial-tachycardia-ablation-in-adults-with-congenital-heart-disease-100590589","NCT06969378","Empiric Pulsed Field Pulmonary Vein Isolation During Atrial Tachycardia Ablation in Adults With Congenital Heart Disease","Inclusion Criteria:\n\n* Adult patients (\\>= 18 years of age) with repaired or unrepaired congenital heart disease and a history of sustained (\\>30 seconds) AT\n\nExclusion Criteria:\n\n* History of sustained AF and\u002For previous catheter or surgical pulmonary vein isolation.",{"count":19,"type":20},[23],"This is a prospective, single-arm intervention trial whereby we will test the safety and efficacy of performing pulmonary vein isolation (PVI) using pulsed field ablation (PFA) in adult patients with congenital heart disease (CHD) who are presenting for atrial tachycardia (AT) ablation.",[31,277,276,316,144,29,317],"Congenital Heart Disease","Catheter Ablation",[170,319,320,202,321,322,172,323],"atrial tachycardia","atrial flutter","congenital heart disease","adult congenital heart disease","catheter ablation","2025-05-05",{"date":326,"type":40},"2025-05-13",{"date":328,"type":20},"2025-07-01",{"date":37,"type":20},{"name":331,"class":103},"Boston Children's Hospital",{"id":333,"slug":334,"hasResults":11,"nctId":335,"briefTitle":336,"officialTitle":337,"acronym":338,"eligibilityCriteria":339,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":340,"targetDuration":4,"studyType":21,"phases":342,"briefSummary":343,"conditions":344,"keywords":345,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":347,"lastUpdatePostDateStruct":348,"startDateStruct":350,"completionDateStruct":352,"leadSponsor":354,"locationsCount":48},"100576925","pulsed-field-ablation-versus-radiofrequency-ablation-for-persistent-atrial-fibrillation-100576925","NCT06791629","Pulsed Field Ablation Versus Radiofrequency Ablation for Persistent Atrial Fibrillation","Pulsed Field Ablation Versus Radiofrequency Ablation for Persistent Atrial Fibrillation: A Randomized, Open-label, Non-inferior Study","PRAISE","Inclusion Criteria:\n\n* 18-80 years\n* Patients with non-valvular persistent atrial fibrillation undergoing their first catheter ablation (AF duration: 3 months to 3 years)\n* Left atrial diameter on parasternal long-axis view of echocardiogram \\\u003C 50 mm\n* Agree to be randomly assigned to the ablation strategy and able to follow up\n\nExclusion Criteria:\n\n* Atrial fibrillation due to reversible causes\n* LVEF \\\u003C 30%\n* Severe congenital heart disease\n* Severe liver or kidney dysfunction (eGFR \\\u003C 15, Child-Pugh grade 3), or history of dialysis\n* History of cardiac surgery, such as coronary artery bypass grafting, mechanical valve or prosthetic valve replacement\n* History of pacemaker implantation, left atrial appendage closure, or patent foramen ovale closure\n* Contraindications to oral anticoagulation\n* Contraindications to right or left heart catheterization\n* Pregnancy\n* Life expectancy \\\u003C 1 year (e.g., advanced malignancy, end-stage renal disease)\n* Currently enrolled in another trial evaluating medical devices or drugs\n* Other situations where the investigator determines the subject is unsuitable for the study",{"count":341,"type":20},700,[23],"This clinical trial aims to compare the efficacy and safety of pulsed field ablation and radiofrequency ablation to treat persistent atrial fibrillation in adults.\n\nParticipants will:\n\nUndergo pulsed field ablation or radiofrequency ablation. Keep follow-up for at least 12 months.",[26,119,29],[346,119,202],"persistent atrial fibrillation","2025-01-23",{"date":349,"type":40},"2025-01-24",{"date":351,"type":20},"2025-02-15",{"date":353,"type":20},"2027-02-15",{"name":305,"class":103},"Pulsed-field Ablation"]